-
The integration of the pharmaceutical industry continues, and many pharmaceutical companies have launched sales this month
Time of Update: 2022-02-22
It is worth noting that on January 6, 2022, Xianju Pharmaceutical also issued a progress announcement on the public listing and transfer of part of the equity of the participating company .
-
2022 Shenzhen Medical Expo Time Address Medical Exhibition
Time of Update: 2022-02-22
2022 Shenzhen International Medical Devices Exhibition 2022 Time: August 17-August 19, 2022 Address: Shenzhen Convention and Exhibition Center (Fuhua 3rd Road, Futian District) China is a country with
-
The supervision of the pharmaceutical packaging material industry is becoming more and more strict, and enterprises need to strengthen standardized management
Time of Update: 2022-02-22
For example, in order to strengthen the quality supervision and management of packaging materials and containers that come into direct contact with drugs and ensure the safety of public medication, according to the 2021 work plan for quality supervision and sampling inspection of pharmaceutical packaging materials in Shandong Province, the Shandong Provincial Food and Drug Administration will organize regional inspection branches to conduct inspections on pharmaceutical packaging in the province.
-
Shanghai biopharmaceutical industry has made good news!
Time of Update: 2022-02-22
Shanghai's biopharmaceutical industry can be described as a series of good news . On January 6, five new cities in Shanghai, Jiading, Songjiang, Qingpu, Fengxian and Nanhui, entered a new stage, and
-
Rectification of online purchases and concealment of the national lowest price will be dealt with
Time of Update: 2022-02-22
Sichuan Pharmaceutical Equipment Tendering and Procurement Service Center January 12, 2022 As we all know, online purchases in many provinces require companies to declare the lowest price in the country .
-
The domestic medical equipment industry ushered in the spring of policy, and the future is bright
Time of Update: 2022-02-21
With the release of the above-mentioned series of policies, especially the "14th Five-Year Plan" at the national level, China's medical equipment industry is expected to accelerate the pace of innovation and research and development, and at the same time accelerate the process of domestic substitution, and the entire industry has a bright future .
-
Zejing Pharmaceutical's ZG005 powder injection clinical trial was approved by FDA
Time of Update: 2022-02-21
On January 20, Zejing Pharmaceutical announced that the clinical trial application for ZG005 powder injection has been approved by the FDA for the treatment of patients with solid tumors .
-
Huadong Medicine's subsidiary DR30303 for Class 1 new drug injection was approved for clinical use
Time of Update: 2022-02-21
On January 20, Huadong Medicine issued an announcement stating that Doer Bio, a subsidiary of Huadong Medicine, received the "Notice of Drug Clinical Trial Approval" (notice number: 2022LP00075) appro
-
A batch of medicines will be adjusted and suspended due to high prices!
Time of Update: 2022-02-21
Recently, the Pharmaceutical Price and Bidding and Procurement Office of Hunan Provincial Medical Insurance Bureau issued the "Notice on Price Correction and Price Restriction of Some Drugs on the Internet".
-
Pharmaceutical companies are digging into the blue ocean market for rare diseases, and patient treatment will be broken
Time of Update: 2022-02-21
It is understood that in order to encourage the research and development and marketing of drugs for rare diseases, China has continuously issued policies to support it in recent years, to attract overseas products to the domestic market, and to increase the emphasis of local pharmaceutical companies on the research of drugs for rare diseases.
-
25 multinational pharmaceutical company executives resign!
Time of Update: 2022-02-21
According to statistics, since the beginning of 2021, more than 100 executives in the pharmaceutical industry have left, 25 of them are executives of multinational pharmaceutical companies, involving AstraZeneca, Eli Lilly, Merck, AbbVie, Roche and other large multinational companies For pharmaceutical companies, the main reasons for leaving are to seek external development and personal reasons .
-
Shanghai: By 2025, the scale of the city's biopharmaceutical industry will exceed 1 trillion yuan
Time of Update: 2022-02-21
On January 20, the "Shanghai Biomedical Industry Development White Paper" was released . The white paper pointed out that by 2025, the scale of Shanghai's biopharmaceutical industry will exceed 1,000
-
The price of these medicines is greatly reduced!
Time of Update: 2022-02-21
For example, the varieties of Chinese patent medicines that patients with chronic diseases are very concerned about are also carrying out local centralized procurement, ushering in price reductions .
-
The next generation of antibody drugs - double antibodies: pharmaceutical companies are enthusiastic about research and development, and the competitive landscape is good
Time of Update: 2022-02-21
Recently, Kangfang Bio announced that its Phase Ib/II clinical trial application of AK104 combined with AK112 has been approved by China's CDE, with or without chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) .
-
The 5th domestic Ruckus Pharma capecitabine tablet was approved for production and deemed to have been reviewed
Time of Update: 2022-02-21
On January 20, the official website of the State Food and Drug Administration showed that Nanjing Rucko Pharma’s Class 4 generic capecitabine tablets were approved for production and deemed to have been reviewed, making it the fifth domestically-produced company to be approved .
-
Under the continuous transformation of the pharmaceutical industry, these three development trends remain unchanged
Time of Update: 2022-02-21
In the future, in order to seize new market development opportunities, pharmaceutical companies are expected to continue to increase investment in innovative drug research and development, and continue to promote the development of high-end generic drugs with core values .
-
More than 500 listed companies disclosed annual report performance forecasts, and the pharmaceutical and biological industry earned a lot of attention
Time of Update: 2022-02-21
On January 19, at least five pharmaceutical companies, including Haichen Pharmaceutical, WuXi AppTec, Jiuzhou Pharmaceutical, and Yabao Pharmaceutical, intensively released their 2021 annual report performance forecasts, and many of them predicted that their net profit would increase by more than 100% in 2021.
-
In order to maintain performance growth, domestic pharmaceutical machine companies will continue to invest in this area
Time of Update: 2022-02-21
In order to maintain performance growth, pharmaceutical machine companies will continue to increase investment in research and development (Photo source: Pharmaceutical Network) At present, the listed companies in the domestic pharmaceutical equipment industry mainly include Xinhua Medical, Tofflon, Chutian Technology, Huasheng Co.
-
In 2030, the scale of this pharmaceutical market is expected to exceed 160 billion yuan
Time of Update: 2022-02-21
3 billion in 2030, with a compound annual growth rate of 11% .
The industry expects that a large number of rare disease drugs with different targets will be launched in the domestic market in the next five years .
-
6 registration review guidelines released involving intraocular lenses, microcatheters, etc.
Time of Update: 2022-02-21
On January 17, the State Food and Drug Administration issued 6 guidelines for medical device registration review, involving disposable high-pressure imaging syringes and accessories, degradable magne
